Sensex, Nifty trade sharply higher despite geopolitical jitters
Indian equity benchmarks traded sharply higher on Friday, mirroring gains in global markets despite fresh geopolitical tensions and concerns over the closure of the Strait of Hormuz.
Indian equity benchmarks traded sharply higher on Friday, mirroring gains in global markets despite fresh geopolitical tensions and concerns over the closure of the Strait of Hormuz.
The company’s board has declared an interim dividend of Rs 11 per equity share of Rs 1 each for FY26.
The conclave aims to position Uttar Pradesh as a leading pharmaceutical and medical device manufacturing hub, supported by robust infrastructure, a vast consumer market, and forward-looking, investor-friendly policies.
According to an official statement, the company’s total revenue from operations in Q2FY26 increased by almost 9% to Rs 14,478.31 crore from Rs 13,291.39 crore, on an year-on-year (YoY) basis.
"While the litigation between Incyte Corporation and the company continues, the preliminary injunction is no longer in effect," the statement by Sun Pharma said.
The subsidiary of Taro Pharmaceutical will acquire 100 per cent stake in the company.
SPARC will also inform the USFDA of the dismissal of the complaint to vacate the 30-month stay, the filing added.
In Asia, all leading bourses witnessed mild to heavy sell-offs on Tuesday after US-China trade war further intensified. In a retaliatory move, China on Monday said it would raise tariffs on US goods worth nearly USD 60 billion.
Pharmaceutical major Sun Pharma's stock gained 4 per cent to touch a high of Rs 406.35 on Monday after it ended Friday's trade lower at more than 8 per cent.
SEBI has advised Larsen and Toubro that its buyback offer is not in compliance with section 68(2)(d) in terms of the net debt and has therefore advised the company not to proceed with the buyback offer.
